REPORTS: Martin Shkreli, the former pharma executive everyone loves to hate, may face new charges
Shkreli already faces charges he defrauded investors, but his lawyers said Tuesday that a trial should be delayed, as there may be new charges filed.
CNBC reports those additional charges against Shkreli and lawyer Evan Greebel should be announced within the month.
To recap, Shkreli has been charged by the federal government with seven counts:
- 2 counts of securities fraud
- 2 counts of conspiracy to commit securities fraud
- 3 counts of conspiracy to commit wire fraud.
Shkreli, the notorious former pharma CEO, made headlines last September after he raised the price of Daraprim, a drug used to treat a parasitic infection called toxoplasmosis, by 5,000%. These charges, however, are not directly related to the price hike, but to events that happened earlier in his career, while he was managing hedge funds.
Shkreli's next court appearance is scheduled for June 6, CNBC reports.